Clinical Trials Logo

Clinical Trial Summary

Orthognathic surgery is a procedure performed to correct dentofacial deformities. It involves osteotomy at the facial skeleton. Considerable pain is expected in the early recovery period. Melatonin is a hormone that is produced naturally by the body. Synthetic Melatonin is available over the counter for the management of sleeping disorder and jetlag. Clinically, Melatonin can also be used to reduce pain and analgesic consumption in patients undergoing surgery. Dexamethasone is a type of steroid. It can suppress the inflammatory response. It is an anti-inflammatory, anti-allergic drug. It is commonly used in head and neck and oral surgery for its anti-inflammatory effect to reduce swelling. This study aims evaluate the efficacy of oral melatonin in the pain reduction following orthognathic surgery. This is a double-blinded randomized controlled trial. We will recruit 87 patients who are scheduled for double-jaw orthognathic surgery to participate in this three-year study. The study lasts for 2 weeks. Participant will be randomly allocated by computer to one of the three groups. (1) Group D will receive dexamethasone only; (2) Group M will receive melatonin only; and (3) Group DM both melatonin and dexamethasone. Postoperative pain level and perioperative plasma levels of inflammatory markers and anti-oxidizing enzymes will be recorded and compared among the study groups.


Clinical Trial Description

Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day. The normal physiological roles of melatonin in the human body are to regulate diurnal rhythm, sleep, mood, immunity, reproduction, intestinal motility, and metabolism. Oral supplemental melatonin has been used in the management of jetlag and other sleep disorders. Recently, melatonin's analgesic, antioxidative, and neuroprotective properties have been highlighted in a number of animal models and a few human trials, although the exact cellular mechanism is still not yet clearly established. In surgical human trials, some conflicting data have been presented regarding the analgesic properties of exogenous melatonin supplement. Whilst the large proportion of studies showed that perioperative administration of melatonin yielded significantly positive effects in the reduction of postsurgical pain, and the reduction of overall morphine consumption, others demonstrated the opposite with no significant effects in pain experience. The reason for this could be related to the dosage, route of administration, and/or time of administration. To date, there is still no consensus on a standardized dosing regimen for melatonin. In non-surgical trials, melatonin has shown promising benefits in many degenerative diseases and conditions related to chronic inflammation and oxidative stress. Amongst many, the reported positive effects of melatonin ranged from the reduction of radiation dermatitis, control of signs and symptoms of ulcerative colitis, management of chronic retinopathy, and reduction of lung oxidative stress in chronic obstructive pulmonary disease patients. Hypothesis: Melatonin can significantly reduce postoperative pain after orthognathic surgery. Antioxidative enzyme activity and level will be elevated and the level of inflammatory markers are reduced. Melatonin has a synergistic effect with dexamethasone. This is a double-blinded randomized controlled trial. We will recruit 87 patients who are scheduled for double-jaw orthognathic surgery to participate in this three-year study. The study lasts for 2 weeks. Participant will be randomly allocated by computer to one of the three groups. (1) Group D will receive dexamethasone only; (2) Group M will receive melatonin only; and (3) Group DM both melatonin and dexamethasone. Postoperative pain level and perioperative plasma levels of inflammatory markers and anti-oxidizing enzymes will be recorded and compared among the study groups. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03995004
Study type Interventional
Source The University of Hong Kong
Contact
Status Suspended
Phase Phase 1
Start date October 2022
Completion date September 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03683953 - The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells Phase 1
Not yet recruiting NCT04554589 - The Off Label Use of Glycopyrrolate in the Adults Intensive Care Unit. Phase 1
Completed NCT04170088 - Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma Phase 2/Phase 3
Not yet recruiting NCT04110808 - Comparative Effect of Hypotensive Anaesthesia on Event Related Potentials, Quantitative Electroencephalograghy Early Phase 1
Terminated NCT04296838 - Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF Phase 2/Phase 3
Recruiting NCT03791372 - Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy Phase 1
Completed NCT04027543 - Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study)
Not yet recruiting NCT03696745 - The Treatment of Premature Infants With Brain Injury by Autologous Umbilical Cord Blood Stem Cells Phase 1
Recruiting NCT03120273 - A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults(Part 2) Phase 1
Unknown status NCT01633099 - Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients Phase 3
Completed NCT05311540 - Zinc Supplementation In Very Low Birth Weight Infants-A Randomised Controlled Trial Phase 4
Completed NCT03488186 - PK-PD Comparative Study of Lansoprazole Capsules and Lansoprazole Enteric-coated Capsules in Healthy Chinese Volunteers Phase 1
Recruiting NCT04042597 - Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma Phase 2
Completed NCT03339882 - Remifemin Preventing the Climacteric Symptoms in Breast Cancer Phase 2
Completed NCT03760900 - Safety of Autologous Cord Blood Cells for Preterm Infants. Early Phase 1
Recruiting NCT03053076 - Safety and Efficacy of Autologous Umbilical Cord Blood Mononuclear Cells Transfusion in Neonates Phase 1
Recruiting NCT04326504 - Dolutegravir and Clinical Outcomes Among ART-recipients in Brazil
Recruiting NCT03700177 - Ropivacaine 0,2% Plus Dexamethasone Versus Ropivacaine 0,2% Plus Placebo in Modified Pectoral Block Phase 4
Completed NCT03228836 - Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients Phase 2
Not yet recruiting NCT03600506 - Dexmedetomidine Adjuvant to General Anesthesia of Abdominal Hysterectomy N/A